SymBiosis Capital Partners, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), SymBiosis Capital Partners, LLC reported 10 stock positions worth $109.5 million. Its top holding was Evommune (EVMN) at 20.0% of the portfolio, followed by Verastem (VSTM, 14.1%) and Amplitech (AMPG, 12.1%).
- Most Recent 13F
- Q1 2026
- Location
- BENTONVILLE, AR
- CIK
- 0002006045
- Portfolio Value
- $109.5M (Q4 2025)
- SEC Filing
- 0002006045-26-000002 ↗ filed Feb 12, 2026
Holdings Value
Holdings 10 stocks · $109.5M
| EVMN Evommune Inc. | 20.03% | 1,280,778 | $21.9M | — |
| VSTM Verastem Inc. | 14.10% | 2,000,000 | $15.4M | — |
| AMPG Amplitech Group Inc. | 12.09% | 2,555,000 | $13.2M | — |
| PGEN Precigen Inc. | 11.45% | 3,000,000 | $12.5M | — |
| IVA Inventiva SA - ADR | 11.04% | 2,600,000 | $12.1M | — |
| NUVB Nuvation Bio Inc. | 10.23% | 1,250,000 | $11.2M | — |
| RANI Rani Therapeutics Holdings Class A | 7.77% | 6,300,000 | $8.5M | — |
| AARD Aardvark Therapeutics Inc. | 5.71% | 476,595 | $6.3M | — |
| CLNN Clene Inc. | 4.13% | 770,495 | $4.5M | — |
| GBIO Generation Bio Co. | 3.45% | 665,000 | $3.8M | — |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 150,000 | $3K | — |
Total filed on the 13F, all lines: $109.5M.
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.